HOME >> MEDICINE >> NEWS
The pharmaceutical industry as political player

The second of four articles about the relationship between the pharmaceutical industry and medicine focuses on the political dynamic between industry and regulatory authorities.

John Abraham from the University of Sussex, Brighton, UK, discusses how political frameworks designed to govern the pharmaceutical industry must, on the one hand, not restrict the flourishing of successful drug development, whilst at the same time providing regulation that is sufficiently robust to protect public health from drugs that are unsafe, ineffective, or unnecessary.

He concludes: "The present drug regulatory systems are insufficiently robust in their political relations with the pharmaceutical industry, because they prevent proper public accountability, are highly vulnerable to industrial capture, and permit scientific experts to have extensive conflicts of interest while providing their expert advice. A regulatory system capable of delivery of publicly defensible assessments, which are uncompromisingly in the interests of public health, is needed."


'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
7-Nov-2002


Page: 1

Related medicine news :

1. Benign separation process being advanced for pharmaceutical industry
2. NYUS Duster cautions against FDA approval of race-based pharmaceutical
3. Biopharmaceutical manufacturing efficiencies signal reduced healthcare costs
4. Physicians have mixed opinions about consumer-targeted pharmaceutical ads
5. Medical residents need training to interact with pharmaceutical representatives
6. UK industry is the loser from parallel trade in pharmaceuticals
7. Nonprofit pharmaceutical seeks drug approval next year
8. Preventing stray chemicals in food, pharmaceutical and industrial products
9. Distortion and lack of openness - Information provision from the pharmaceutical industry
10. Former insider hits out at FDAs links with pharmaceutical industry
11. Pennsylvania chemist wins national award for pharmaceutical research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The pharmaceutical industry political player

(Date:5/23/2013)... OR (PRWEB) May 23, 2013 Sharon ... launch of a new product to supplement natural tear ... environmental conditions. The product, Nature’s Tears® EyeMist®, according to ... that releases a 100% fresh water mist to the ... , Kleyne, who describes herself as “educator, inventor, ...
(Date:5/23/2013)... 23, 2013 US demand for ... annually to $8.0 billion in 2017. Expansion of ... need for high-performance plastic films that offer such ... resistance in packaging and construction applications. Additionally, the ... such as photovoltaic modules biodegradable products, and pharmaceuticals ...
(Date:5/23/2013)... Atlanta, GA (PRWEB) May 23, 2013 ... are becoming more popular. But according to Mike Whitfield, ... inexpensive piece of equipment like the medicine ball can ... workout. Mike Whitfield runs BodyweightTorch.com, a website in which ... free that uses no equipment. Recently, he shared a ...
(Date:5/23/2013)... 23, 2013 Medical device development is ... Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s ... Pediatric Surgical Innovation Symposium will be held June 13, ... It will address critical issues in pediatric surgical innovation ... available on the Sheikh Zayed Institute website. , ...
(Date:5/23/2013)... 23, 2013 Studies show that kids and ... week are less likely to be overweight, less likely to ... academically, and have better relationships with their parents. ... according to family dinner expert and advocate Aviva Goldfarb ... by 33 percent. When families do eat together, average mealtimes ...
Breaking Medicine News(10 mins):Health News:Water Entrepreneur Announces First Ever Personal Dry Eye Humidifier 2Health News:U.S. Specialty Films Market Worth $8 Billion & Packaging Drives Industry by 2017 Says New Research Report at ReportsnReports.com 2Health News:U.S. Specialty Films Market Worth $8 Billion & Packaging Drives Industry by 2017 Says New Research Report at ReportsnReports.com 3Health News:U.S. Specialty Films Market Worth $8 Billion & Packaging Drives Industry by 2017 Says New Research Report at ReportsnReports.com 4Health News:Unique Ab Exercise, the Medicine Ball Chop, Released from BodyweightTorch.com 2Health News:Children’s National to Host Symposium on Medical Device Development 2Health News:Family Dinner Expert and Cookbook Author Announces “Family Dinner Challenge” 2
(Date:5/23/2013)... -- SynCardia Systems, Inc. ( www.syncardia.com ), manufacturer of ... CE ( Europe ) approved Total Artificial ... Scotland , which boasts more than ... Total Artificial Heart powered by the Freedom® portable ... one of the most advanced exhibitions of its kind. ...
(Date:5/23/2013)...  Echo Pharma Acquisition Limited ("Royalty Pharma") announced today ... Threshold from 90 percent to 50 percent of Maximum ... with the terms of the Revised Offer Document issued ... Under the terms of the Increased Offer, Royalty Pharma ... ) for $12.50 per share in cash. The Increased ...
(Date:5/23/2013)... , May 23, 2013 ... MKT: NSPR), the leader in embolic protection stents, ... (MGuard for Acute ST Elevation Reperfusion) trial demonstrating ... bare metal and drug eluting stents in all-cause ... patients.  Results from the trial were presented at ...
Breaking Medicine Technology:Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
Cached News: